Why Is ASCENDIS PHARMA A/S (ASND) Stock Moving Today?

Why ASND stock is down today

Ascendis Pharma A/S (ASND) fell 9.49% to $239.77 in afternoon trading on September 15, 2026. The decline followed a downgrade from Raymond James, which cut the stock from Strong Buy to Outperform. The move came amid a broader sell-off in the sector and uncertainty around the company's strategic direction following the termination of its collaboration with Novo Nordisk.

What Happened

Raymond James downgraded Ascendis Pharma stock to Outperform from Strong Buy, citing a shift in partnership dynamics. This downgrade occurred as the company presented at the Morgan Stanley 24th Annual Global Healthcare Conference. The stock had previously regained rights to its weight-loss technology after the Novo Nordisk collaboration ended in November 2024. Despite announcing a $400 million share repurchase program, the stock continued to decline. The Fly reported the stock down 12.1% and 12.8% at different points during the session, reflecting heightened volatility.

What The Data Shows

Over the last eight trading sessions, the stock has fallen 13.8%, from $268.17 to $231.13. On September 15, it printed 20 fresh 52-week lows. Recent insider transactions include a sale by Mads Bodenhoff, SVP and PAO, on September 8, and a purchase by Jean Jacques Bienaime, a director, on August 14. Over the last 90 days, insiders have bought $493,000 worth of shares and sold $811,000 worth. The stock is currently trading within its 52-week range of $186.05 to $282.15.

What To Watch

Investors should monitor the company's next earnings report and any further analyst actions. The stock's performance may also be influenced by broader market trends, particularly in the healthcare sector.